Drugs / Akynzeo
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Akynzeo | — | 2015-05-27 | europa.eu ↗ |
| Approved | US (FDA) | AKYNZEO | — | 2014-10-10 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04362449 | Jan 2019 → Feb 2023 | gallbladder cancer | Imperial College Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03668639 | Sep 2018 → Mar 2023 | cervical cancer, chemotherapy-induced toxicity | Christina Ruhlmann | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06065722 Comparator | Sep → Dec 2023 | chemotherapy-induced toxicity | Simon Williamson Clinic | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Akynzeo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03668639 ↗ |
| Action | Inhibit | “Akynzeo contains a combination of the neurokinin-1 receptor antagonist netupitant and the serotonin receptor antagonist palonosetron.” NCT03668639 ↗ |
| Route | Oral | “Akynzeo is administered as an oral drug” NCT04362449 ↗ |